Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

SA Transcripts 162.16K Followers Follow Madrigal Pharmaceuticals, Inc. ( MDGL ) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 1:00 PM EDT Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Cantor Fitzgerald & Co., Research Division All right. Welcome, everyone, to day 2 of Cantor's Global Healthcare Conference. My name is Prakhar Agrawal. I'm a biotech analyst at Cantor. And for the next session, we are very excited to host the team of Madrigal. Joining us today, we have the entire management team, Bill, CEO; Mardi, CFO; and David, Chief Medical Officer. Thank you so much for taking the time to join our conference. William Sibold CEO, President & Director Thank you. Question-and-Answer Session Prakhar Agrawal Cantor Fitzgerald & Co., Research Division Maybe, Bill, we can start off with just level-setting expectations. Coming out of 2Q, what were some of the key highlights for you internally on Rezdiffra's performance and things that maybe Street fully underappreciated? William Sibold CEO, President & Director Yes. Well, first of all, thanks for having us, Prakhar. We're really happy to be here. Q2 was a great quarter for us. If you look at it from any of the metrics that we share, starting with $364 million in sales. That puts us in a very, very elite group when you take out some of the already mega blockbusters that exist. There's very few companies that could put up a quarter like that with some differences, and I'll get to that in a second. We also announced that we had greater than 49,000 patients. That was the end of Q2, but we also said that we crossed the 50,000 mark in July, which is